Product news

Share this article:
The FDA has approved Eli Lilly's Cymbalta (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder. The approval makes Cymbalta the first serotonin-norepinephrine reuptake inhibitor approved for reducing pain in patients with fibromyalgia. 

Allergan said the FDA has approved Trivaris (triamcinolone acetonide injectable suspension), a synthetic glucocorticoid corticosteroid with anti-inflammatory action to treat sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.